MORE VDRM News this Morning stock has a 10Mil Float They are OTC Pink Current!
Share structure AS follows:
Shares Outstanding 61,062,116 a/o Aug 13, 2014
Float 10,428,638 a/o Aug 13, 2014
Authorized Shares 150,000,000 a/o Aug 13, 2014
THE NEWS!!
ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA
LOS ANGELES, Oct. 30, 2014 /PRNewswire/ -- ViaDerma, Inc. (OTCQB: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, has recently released a revolutionary new wound care drug called TetraStem. TetraStem is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs. The drug is FDA registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns, but has also shown to be effective in fighting methicillin-resistant Staphyloccus aureus (MRSA) infections.
According to Mayo Clinic, Staph bacteria are normally found on the skin or in the nose of about one-third of the population. The bacteria are generally harmless unless they enter the body through a cut or other wound, and even then they usually cause only minor skin problems in healthy people. MRSA infection is caused by a strain of staph bacteria that's become resistant to the antibiotics commonly used to treat ordinary staph infections. This can allow the infections to spread and sometimes become life-threatening. According to the CDC MRSA kills about 11,000 people each year in the United States.
ViaDerma's founder and CEO Dr. Christopher Otiko comments, "Initial case studies involving TetraStem have showed remarkable success. The most memorable was a woman in Florida who was on IV antibiotics for Systemic MRSA. The patient's MRSA infection was drug resistant and the usual medications were not working. However, after advising the patient to apply TetraStem directly to her neck and wrist the patient was symptom-free within two months."
ViaDerma is currently in negotiations to test TetraStem at hospitals in Florida with plans to expand the use of the drug across America. TetraStem is currently being sold in various retail outlets. For more information about TetraStem, please visit www.viadermalicensing.com.
About ViaDerma, Inc.
Founded in 2014 by Dr. Christopher Otiko, ViaDerma, Inc. (VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. ViaDerma's lead product, TetraStem, uses an innovative transdermal delivery method to apply almost any active ingredient to a topical drug. This patent-pending dual carrier transdermal technology may be applied in products within the medical and cosmetic markets. For more information, please visit www.viadermalicensing.com.
DISCLAIMER:
THE PENNY STOCK LOUNGE / Struks Penny Lounge nor any of the moderators, members or affiliates at The Penny Stock Lounge are licenced or certified investment advisors; as such any and all dissemination of information contained in Live Chats, Topics, Text Messages, e-mails or any other other forms of communication means should be taken for "information or entertainment purposes only!" Doing your own proper & thorough Due Diligence is always recommended, strongly suggested and advised!
You agree that the Service should not be interpreted as investment advice, as an endorsement of any security, or as an offer to buy or sell any security. The Penny Stock Lounge is not a registered broker dealer, or financial advisor. The Penny Stock Lounge does not provide personal investment advice. You also understand and agree that, from time to time, any or all of the information providers or their affiliates may hold positions in securities mentioned and that they may trade for their own account based on this information.
Market Data 
Markets 
AI
